| 1 | Impact of monoclonal antibody treatment on hospitalization and mortality among non- |
|---|---|
| 2 | hospitalized adults with SARS-CoV-2 infection |

3

| 4 | Au | thors: J. Ryan Bariola MD ¹ , Erin K. McCreary PharmD ¹ , Richard J. Wadas MD ² , Kevin E. |
|----|-----|---|
| 5 | Kij | p PhD ³ , Oscar C. Marroquin MD ³ , Tami Minnier MSN, RN ⁴ , Stephen Koscumb BS ³ , Kevin |
| 6 | Co | llins BS ³ , Mark Schmidhofer MD ⁵ , Judith A. Shovel BSN RN ⁴ , Mary Kay Wisniewski, MT |
| 7 | MA | A COM ⁴ , Colleen Sullivan MHA ⁶ , Donald M. Yealy MD ² , David A Nace MD MPH ⁷ , David |
| 8 | Т. | Huang MD MPH ^{2,8,9} , Ghady Haidar MD ¹ , Tina Khadem PharmD ¹ , Kelsey Linstrum MS ^{6,9} , |
| 9 | Ch | ristopher W. Seymour MD MSc ^{6,9} , Stephanie K. Montgomery MS ^{6,9} , Derek C. Angus MD |
| 10 | Mł | PH FRCP ^{6,8,9} , Graham M. Snyder MD SM ¹ |
| 11 | 1. | Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of |
| 12 | | Medicine, Pittsburgh, PA, USA |
| 13 | 2. | Department of Emergency Medicine, University of Pittsburgh School of Medicine, |
| 14 | | Pittsburgh, PA, USA |
| 15 | 3. | Clinical Analytics, University of Pittsburgh Medical Center, Pittsburgh, PA, USA |
| 16 | 4. | Wolff Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA |
| 17 | 5. | Division of Cardiology, Dept of Medicine, University of Pittsburgh School of Medicine, |
| 18 | | Pittsburgh, PA, USA |
| 19 | 6. | UPMC Health System Office of Healthcare Innovation, Pittsburgh, PA, USA |
| 20 | 7. | Division of Geriatric Medicine, Department of Medicine, University of Pittsburgh, |
| 21 | | Pittsburgh, PA, USA |
| 22 | 8. | Department of Critical Care Medicine, University of Pittsburgh School of Medicine, |

23 Pittsburgh, PA, USA

| 24 | 9. Clinical Research Investigation and Systems Modeling of Acute Illness (CRISMA) Center, |
|----|---|
| 25 | Department of Critical Care Medicine, University of Pittsburgh School of Medicine, |
| 26 | Pittsburgh, PA, USA |
| 27 | |
| 28 | Corresponding Author: |
| 29 | Graham M. Snyder, MD SM |
| 30 | Address: 3601 Fifth Avenue, Suite 150, Pittsburgh, PA 15213 |
| 31 | Phone/Fax: 412-647-6718/412-692-2768 |
| 32 | Email: snydergm3@upmc.edu |
| 33 | Keywords: COVID-19, SARS-CoV-2, monoclonal antibodies, bamlanivimab, etesevimab, |
| 34 | casirivimab, imdevimab |
| | |

36 ABSTRACT

Background: Monoclonal antibody (mAb) treatment may prevent complications of COVID-19.
We sought to quantify the impact of bamlanivimab monotherapy on hospitalizations and
mortality, as well as Emergency Department (ED) visits without hospitalization, among
outpatients at high risk of COVID-19 complications.

Methods: We compared patients receiving mAb to patients who met criteria but did not receive mAb from December 2020 through March 2021. The study population selection used propensity scores to match 1:1 by likelihood to receive mAb. The primary outcome was hospitalization or all-cause mortality within 28 days; the secondary outcome was hospitalization or ED visit without hospitalization within 28 days. Odds ratios (OR) calculation used logistic regression modeling including propensity score and mAb receipt predictors.

47 **Results**: The study population included 234 patients receiving mAb and 234 matched

48 comparator patients not receiving mAb. Patients receiving mAb were less likely to experience

49 hospitalization or mortality (OR 0.31, 95% confidence interval [95%CI] 0.17-0.56, p=0.00001)

and hospitalization or ED visit without hospitalization (OR 0.50, 95%CI 0.43-0.83, p=0.007).

51 The impact of mAb was more pronounced in prevention of hospitalization (among all age

52 groups, OR 0.35, 95% CI 0.19-0.66, p=0.001) than mortality or ED visit without hospitalization,

and most strongly associated with patients age 65 years and older (primary outcome OR 0.28,

54 95%CI 0.14-0.56, p=0.0003).

55 **Conclusions**: Bamlanivimab monotherapy was associated with reduction in the composite

56 outcome of hospitalizations and mortality in patients with mild-moderate COVID-19. The

57 benefit may be strongest in preventing hospitalization in patients ages 65 years or older.

58 INTRODUCTION

Monoclonal antibodies (mAbs) bind to the SARS-CoV-2 spike (S) protein and block viral 59 entry into host cells, neutralizing the virus.¹⁻⁵ Between November 2020 and February 2021 four 60 mAbs provided as three treatments received Food and Drug Administration Emergency Use 61 Authorization (EUA) for treatment of patients with mild to moderate COVID-19 within 10 days 62 63 of symptom onset: bamlanivimab 700mg (LY-coV555; Eli Lilly), etesevimab 1,400mg (LY-CoV016; Eli Lilly), casirivimab 1,200mg (REGN10933; Regeneron), imdevimab 1,200mg 64 (REGN10987). Several clinical trials currently evaluate mAbs for prevention or treatment of 65 COVID-19; however, real-world data are limited, and the role of mAbs for patients with 66 COVID-19 remains controversial.^{3, 5} 67 Use of mAb therapy is low in the United States despite widespread drug availability due 68 to lack of robust efficacy data, operational challenges with outpatient infusions, and patient 69 access issues.⁶ Our health system established a mAb program in November 2020 to decrease 70 71 COVID-19-related complications for patients with mild-moderate illness and expand access to care for underserved patients with COVID-19. Initially, only bamlanivimab monotherapy was 72 available; our evaluation and distribution process has been described elsewhere.⁷ This study 73 74 quantifies the impact of bamlanivimab monotherapy on hospitalizations, mortality, and Emergency Department (ED) visits among outpatients at high risk of progressing to severe 75 76 COVID-19. We also explored whether patient age, body mass index, and timing of infusions 77 relative to initial diagnosis had any association with response to therapy.

78

79 **METHODS**

80 Study Setting

| 81 | UPMC is a 40-hospital integrated academic healthcare system providing care principally |
|-----|--|
| 82 | within central and western Pennsylvania (USA). After the November 2020 EUA was granted for |
| 83 | bamlanivimab, UPMC rapidly established 16 outpatient infusion centers across all served |
| 84 | geographical areas. We also infused mAb at our UPMC Senior Communities (i.e., long-term care |
| 85 | facilities), patient homes (via collaboration with a home infusion company), and behavioral |
| 86 | health units. Physicians referred patients via outpatient and oncology electronic medical records |
| 87 | (EMR) or paper order including non-UPMC providers. A centralized team with pharmacists and |
| 88 | physicians reviewed orders daily to confirm EUA criteria; decentralized nursing teams then |
| 89 | contacted and scheduled eligible patients for infusions. This study was approved by the UPMC |
| 90 | Quality Improvement Review Committee (Project ID 2882 and Project ID 3116). |
| 91 | We used the EMR to access all key clinical data, including detailed sociodemographic |
| 92 | and medical history data, diagnostic and clinical tests conducted, surgical and other treatment |
| 93 | procedures performed, prescriptions ordered, and billing charges on all outpatient and in-hospital |
| 94 | encounters, with diagnoses and procedures coded based on the International Classification of |
| 95 | Diseases, Ninth and Tenth revisions (ICD-9 and ICD-10, respectively). |
| 96 | We linked the deidentified primary data sources using common variables within the |
| 97 | UPMC data systems aggregated in its Clinical Data Warehouse that include: (i) Medipac, the |
| 98 | admit, discharge and transfer registration and hospital-based billing system; (ii) Cerner, the |
| 99 | inpatient EMR for relevant clinical information for bedded patients at a UPMC inpatient |
| 100 | hospital; (iii) Epic, the UPMC EMR for ambulatory office visits owned by UPMC; and (iv) Aria, |
| 101 | the EMR utilized in most ambulatory Cancer Centers at UPMC for both radiation oncology and |
| 102 | medical oncology. ⁸ |
| 102 | Study Dopulation |

103 Study Population

The study population was derived from patients who received bamlanivimab from 104 December 9, 2020 to March 3, 2021. Patients were candidates for therapy based on criteria 105 106 consistent with EUA criteria including: recently diagnosed mild to moderate COVID-19 (with a positive polymerase chain reaction or antigen test for SARS-CoV-2 virus within 10 days of the 107 date the test was obtained); body mass at least 40 kg; age ≥ 65 years or age ≥ 12 years with a 108 109 medical condition conferring high risk of COVID-19 progression to severe disease and/or hospitalization.⁹ Patients were included in the study population if they completed the mAb 110 111 infusion and had attainment of one of the study outcomes of interest within 28 days of infusion, or had 28 days of follow-up without an outcome. 112

We also derived a comparator group from the same at-risk population by identifying non-113 hospitalized patients with a positive polymerase chain reaction or antigen test for SARS-CoV-2 114 during the same time period who were eligible for mAb infusion based on our modified EUA 115 116 criteria but not infused. Similar to the group receiving mAb, comparator patients were included 117 in the study population if they had attainment of one of the study outcomes of interest within 28 days or had 28 days of follow-up without an outcome. For infused patients, the 28-day follow-up 118 period commenced on the date of their infusion. For comparator patients, the follow-up period 119 120 commenced two days after their SARS-CoV-2 test result date, which corresponded to the earliest time from test positivity to initiation of treatment for infused patients. 121

122 Study Outcomes

The primary outcome was hospitalization or all-cause mortality within 28 days of meeting study eligibility (day of infusion for the group receiving mAb, 30 days after test positivity for the non-infused group). We assessed in-hospital mortality using the discharge disposition of "Ceased to Breathe" sourced from the inpatient EMR and out-of-hospital deaths

from the Social Security Death Index. The secondary outcome was hospitalization or 28-day Emergency Department (ED) visit without hospitalization. To understand the contribution of individual elements of the primary and secondary composite outcomes, we also analyzed the frequency of individual events: ED visit without hospitalization, hospitalization, and mortality within 28 days.

132 Statistical Methods

After identifying patients in the study population receiving mAb, we selected from the at-133 risk comparator population individuals matched by propensity score.^{10, 11} Age is a strong 134 135 predictor for complications of COVID-19 and the prevalence of high-risk medical conditions vary substantially by patient age.^{12, 13} We anticipated that differences in patient profiles between 136 infused and non-infused patients would vary by age because of the age-specific criteria for 137 bamlanivimab contained in the EUA. Moreover, immunosenescence occurs with aging, so we 138 anticipated age to be a potential effect modifier in the relationship between mAb receipt and 139 study outcomes.¹⁴ Therefore, we planned *a priori* to select non-infused patients using propensity 140 scores within age strata consistent with the EUA criteria: less than 55 years, 55 years to less than 141 65 years, and 65 years of age and older.⁹ Patients receiving mAb infusion and the selected 142 143 comparator patients across all age strata were then combined to constitute the study population. We used this approach, rather than initially running a single model from the full dataset, to 144 145 optimize selection of appropriate controls. To illustrate, in the full dataset, the prevalence of 146 history of morbid obesity was 27.4% versus 24.9% (p=0.37) in infused vs. non-infused patients, respectively, whereas in the subset of patients age 55 to < 65 years, the respective prevalence 147 148 was 66.7% vs. 22.4% (p<0.00001). Thus, we believe that more robust matching of infused to

non-infused patients was achieved by capturing and adjusting for the important differences inpresenting profiles within each age-specific cohort.

151 Propensity scores were derived using logistic regression models fit from a multitude of variables in separate age-stratified groups with treatment with mAb as the response variable and 152 forward stepwise selection of measured pre-treatment explanatory variables at p < 0.15 (see 153 154 Supplemental Table 1 for listing of variables used in the propensity score models). We included 155 variables deemed biologically relevant (e.g. age, gender, Charlson Comorbidity Index score) into 156 all models prior to stepwise selection. We used 1:1 propensity score matching with a maximum 157 propensity score probability difference of 0.01 to construct equal size matched infused and noninfused groups within age strata. We did not impute missing values for variables used in deriving 158 the propensity scores but did assess whether patients with propensity scores (i.e., full covariate 159 data) versus those with missing propensity scores were similar in terms of age, gender, and race 160 distributions (to assess randomness of missing data). 161

162 We compared characteristics of infused versus non-infused patients using student *t*-tests for continuous variables and chi-square tests for categorical variables. Because in this 163 observational study we must infer the time at risk for non-infused patients (starting at the time 164 165 they would have received mAb had they been referred for care, conservatively using two days after SARS-CoV-2 testing), we compared the distribution of time from beginning of follow-up to 166 167 study outcome among patients receiving mAb infusion and those who did not, both in the at-risk 168 and matched populations (Supplemental Table 2). Crude 28-day rates of the study outcomes were described by infusion status. For the propensity matched patient analysis of primary and 169 170 secondary outcomes, as well as individual elements of the composite outcomes (ED visit without 171 hospitalization, hospitalization, mortality) we fit logistic regression models with the derived

propensity scores (i.e., predicted probability of being treated with mAb) as a continuous variableto control for confounding, with mAb receipt as the predictor of interest in the model.

174 We also performed one sensitivity and three exploratory analyses. As a sensitivity analysis, we used the propensity score (i.e., predicted probability of being treated with mAb) as a 175 continuous variable to control for confounding and evaluate study outcomes in a larger 176 177 unmatched cohort of patients who did and did not receive mAb. We did not employ the use of inverse probability weighting given the very large imbalance of eligible bamlanivimab treated 178 179 versus not infused patients. We postulated that mAb may be more efficacious in the potentially 180 immunosenescent older population. Thus, we evaluated the study outcomes within the predefined age strata. In the second exploratory analysis among the larger unmatched cohort, an 181 interaction term of mAb x BMI was created to examine potential effect modification of treatment 182 with mAb by BMI.¹⁵ To identify a potential benefit of prompt (versus delayed) administration of 183 184 mAb, as a third exploratory analysis we compared the rates of three outcomes – ED visit without 185 hospitalization, hospitalization, and mortality – within the analysis group stratified by time from diagnosis to infusion: 0 to 2 days, 3 to 4 days, 5 to 7 days, and 8 to 10 days. 186

Study outcomes are described with effect estimate (odds ratio [OR]) and 95% confidence
interval (95%CI). We set the alpha error at 0.05 for univariate comparisons of baseline
characteristics by infusion status as well as for adjusted odds ratios. All analyses were performed
using the SAS System (Cary, NC), version 9.4. Methods and results are reported in accordance
with The REporting of studies Conducted using Observational Routinely-collected health Data
(RECORD) statement (see Supplemental Table 3).¹⁶

193

194 **RESULTS**

195 Study Population

During the study period (December 9, 2020 through March 3, 2021), 636 patients
received mAb. Four hundred and sixty-three (72.8%) patients achieved a study outcome or
completed 28-day follow-up time and are in the analysis group, with the last infused patient who
did not die treated on February 3, 2021. The non-infused at-risk population included 17,599
COVID-19 non-hospitalized patients potentially eligible for mAb according to modified EUA
criteria, of which 16,565 (94.1%) achieved study outcome or had sufficient follow-up time.

202 Table 1 shows a comparison of baseline characteristics of the infused versus non-infused patients both in the unmatched at-risk population and matched study population. The unmatched 203 populations are significantly different on most characteristics with patients receiving mAb 204 infusion demonstrating higher frequencies of these medical conditions. After propensity score 205 206 matching within age strata, 234 patients receiving mAb infusion and 234 patients not receiving 207 mAb were included in the study population. After propensity matching, all matched and selected 208 unmatched variables did not differ statistically between patients who received versus did not receive mAb infusion. 209

210 Primary and Secondary Outcomes

Among the 234 propensity-matched patients receiving mAb infusion, 15 (6.4%) were hospitalized, 4 (1.7%) died, and 16 (6.8%) had an ED visit without hospitalization (**Table 2**). Among the 234 propensity-matched patients not receiving mAb infusion, 38 (16.2%) were hospitalized, 12 (5.1%) died, and 15 (6.4%) had an ED visit without hospitalization. **Figure 1a** shows the frequency of the primary outcome (28-day hospitalization or mortality) and the secondary outcome (hospitalization or ED visit without hospitalization) among the matched patients receiving mAb versus those not receiving mAb infusion. In the propensity adjusted

analyses (Table 2), patients receiving mAb had an estimated 69% lower odds of hospitalization
or mortality (OR 0.31, 95% CI 0.17-0.56) and estimated 50% lower odds of hospitalization or
ED visit without hospitalization (OR 0.50, 95% CI 0.43-0.83). Figure 1b shows the frequency
of the individual elements of the composite primary and secondary outcomes (ED visit without
hospitalization, hospitalization, mortality) among the matched patients receiving mAb versus
those not receiving mAb infusion, and Table 2 lists the corresponding ORs and 95% confidence
intervals.

225 Sensitivity and Exploratory Analyses

226 **Supplemental Table 4** provides risk estimates for the composite primary and secondary outcomes, and outcomes comprising the composite outcomes, in an unmatched cohort of patients 227 receiving monoclonal antibody infusion and an at-risk population of patients not receiving 228 229 monoclonal antibody infusion, adjusted for propensity to receive mAb. The 236 patients with non-missing covariate data who received mAb had an estimated 59% lower odds of 230 231 hospitalization or mortality than the 16,565 patients who did not receive mAb (propensity-score adjusted OR 0.41, 95% CI 0.24-0.70). Thus, study results were consistent between the matched 232 and unmatched group analyses. 233

Table 2 provides adjusted ORs for the primary and secondary outcomes, plus individual outcomes comprising the composite outcomes, stratified by age. In propensity score adjusted analyses for the 28-day rate of hospitalization or mortality, there was no differential treatment effect by BMI. P-values for the interaction term of mAb x BMI were 0.55, 0.81, 0.38, and 0.84 for all patients and in the age groups less than 55 years, 55 to less than 65 years, and 65 years and older, respectively. Supplemental Figure 1 indicates among patients aged 65 years and older lower composite hospitalization or mortality event rates comparing mAb infused to non-

infused patients across all BMI categories. Figure 2 indicates that among patients in the study
population receiving mAb infusion, those who received their infusion within 4 days of their
positive SARS-CoV-2 test result had lower 28-day rates of ED visit without hospitalization and
hospitalization than patients who received their infusion 5 days or more after their positive
SARS-CoV-2 test result. Rates of mortality were low and similar by timing of infusion.
Finally, age, gender, and race distributions between patients with full covariate data and
those with missing data were similar (data not shown).

248

249 **DISCUSSION**

Our observational study suggests a benefit of mAb treatment in reducing the risk of 250 COVID-19 complications for patients at higher risk of severe disease. Initial reports of 251 252 bamlanivimab 700 mg in outpatients showed improvement of symptoms at day 11 for the entire study population³ and numerically fewer hospitalizations and ED visits at day 29 (1.6% vs 253 6.3%).¹⁷ A post hoc analysis in BLAZE-1 of those 65 or older or with BMI of 35 kg/m² or 254 greater demonstrated a larger numerical benefit, 2.7% vs 13.5%.³ In this report of our 255 experience, we identified a similar association between bamlanvimab monotherapy and 256 257 hospitalization or mortality in a propensity matched analysis with an OR of 0.31, or a 69% lower odds of hospitalization or mortality. 258

In our health system, rates of hospitalizations and ED visits in patients aged 65 years or older were higher than the clinical trial, yet a benefit to mAb treatment was nonetheless observed. This benefit occurred through decreased hospitalizations and mortality (OR 0.28) as well as for hospitalizations alone (OR 0.32) and for hospitalizations or ED visits without

hospitalization (OR 0.43). We also identified a tendency of mortality benefit in this age group
(OR 0.35), although our sample size and event limit declaring an association.

Cumulatively our report shows benefit for patients across several possible outcomes, and we consider this highly relevant from a clinical standpoint. While we did not observe statistically significant differences in the primary or secondary outcomes in younger age groups, the odds ratios in the group aged 55 to less than 65 years, and few outcomes in those age less than 55 years suggest an effect may exist though potentially smaller in magnitude.

270 We identified greater benefits with administration within 4 days of symptom onset, 271 particularly regarding rates of hospitalization. While the EUA allows for use within 10 days of symptom onset, the median duration of symptoms prior to receiving bamlanivimab 700 mg was 272 5 days in BLAZE- 1^3 . As with other passive antibody therapies, this is consistent with the 273 supposition that earlier treatment is better, and health systems may reasonably evaluate a shorter 274 275 window of eligibility for mAb therapy. Our analysis shows that benefits in the elderly are 276 independent of BMI. The potential differential benefit of mAb therapy for COVID-19 in patients with this and other co-morbidities warrants more focused analysis. 277

There are several limitations of our study. Given our design, it is not surprising that there 278 279 were several baseline differences between those infused and not infused in other age groups. We mitigated confounding with propensity score modeling of closely matched groups of patients, 280 281 and a sensitivity analysis using propensity-score adjusted unmatched patients not receiving mAb 282 infusion affirmed the findings. Furthermore, the group receiving mAb had more comorbid 283 conditions predisposing to the primary and secondary outcomes, which may underestimate the 284 magnitude of the treatment effect if there was residual confounding. We cannot reliably 285 distinguish the presence, extent, or severity of symptoms in our data set, all of which may impact

effectiveness. Additionally, viral loads in blood or any site were not measured in our data set,
limiting any insights based on this variable. The time to event in both treated and untreated
groups were similar, suggesting that ED visit or hospitalization did not account for why the
untreated population did not receive mAb. Viral loads in blood or any site were not measured in
our data set, limiting any insights based on this variable.

291 We did not have information regarding variant strains of SARS-CoV-2 prior to or after 292 bamlanivimab monotherapy. While reported rates of clinically concerning variants were low in 293 Pennsylvania during much of this time frame, there is concern that use of bamlanivimab monotherapy will lead to escape variants and/or that variants are underreported.¹⁸ We were 294 unable to evaluate any such existing prevalence or emergence in our patients. Finally, during the 295 time of this study, we utilized bamlanivimab monotherapy exclusively, so we are unable to 296 297 comment on any comparison to the other available monoclonal antibodies for treatment of mildmoderate COVID-19 infection. On March 24th, the United States Department of Health and 298 Human Services announced they would no longer supply sites with bamlanivimab alone due to 299 concern about increased rates of resistant variants.¹⁹ Many of our patients received bamlanvimab 300 when the rates of resistant variants in this country was low, thus explaining why we still saw 301 302 benefit with bamlanivimab monotherapy. Going forward it will be critical to better define the roles of the various available therapies and where each may be best utilized, including possibly a 303 304 continued role for bamlanivimab monotherapy.

In our non-experimental design, we observed that bamlanivimab monotherapy is associated with decreased hospitalization rates and mortality in patients with mild-moderate COVID-19 infection, particularly among those 65 years or older, and may likely extend to younger patients as well. This benefit appears more likely when administered early after

- 309 diagnosis. Further study can confirm our observations and investigate the role of mAb treatment
- 310 in other high-risk subgroups and the use of various mAb regimens.

Acknowledgements: The authors thank the clinical staff of the UPMC monoclonal antibody 311 infusion centers as well as the support and administrative staff behind this effort, including but 312 not limited to: Debbie Albin, Jennifer Dueweke, Robert Shulik, Amy Lukanski, Rozalyn Russell, 313 Debra Rogers, Jesse Duff, Kevin Pruznak, Jennifer Zabala, Trudy Bloomquist, Daniel Gessel, 314 LuAnn King, Jonya Brooks, Libby Shumaker, Betsy Tedesco, Sarah Sakaluk, Kathleen Flinn, 315 316 Susan Spencer, Le Ann Kaltenbaugh, Michelle Adam, Meredith Axe, Melanie Pierce, Debra Masser, Theresa Murillo, Sherry Casali, Jim Krosse, Jeana Colella, Rebecca Medva, Jessica 317 Fesz, Ashley Beyerl, Jodi Ayers, Hilary Maskiewicz, Mikaela Bortot, Amy Helmuth, Heather 318 319 Schaeffer, Janice Dunsavage, Erik Hernandez, Ken Trimmer, Sheila Kruman, Teressa Polcha, and their entire teams. We also thank the U.S. federal government and Pennsylvania Department 320 321 of Health for the provision of monoclonal antibody treatment. Funding Statement: This work received no external funding. 322 Conflict of Interest Disclosure: None of the authors received any payments or influence from a 323 324 third-party source for the work presented, and none report any potential conflicts of interest.

326 **References**

- 1. Jones BE, Brown-Augsburger PL, Corbett KS, et al. LY-CoV555, a rapidly isolated
- 328 potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2
- infection. *bioRxiv*. Oct 1 2020;doi:10.1101/2020.09.30.318972
- 2. Myron S. Cohen1, Ajay Nirula2, Mark Mulligan3, Richard Novak4, Mary Marovich5,
- Alexander Stemer6, Andrew C. Adams2, Andrew E. Schade2, Jack Knorr2, Jay L. Tuttle2,
- Janelle Sabo2, Paul Klekotka2, Lei Shen2, Daniel M. Skovronsky2, for BLAZE-2 study team
- 333 (Lilly/NIAID/CoVPN). Bamlanivimab prevents COVID-19 morbidity and mortality in nursing-
- home setting. Oral abstract #121. Presented at Virtual CROI 2021.
- 335 3. Gottlieb RL, Nirula A, Chen P, et al. Effect of Bamlanivimab as Monotherapy or in
- 336 Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A
- 337 Randomized Clinical Trial. Jama. Feb 16 2021;325(7):632-644. doi:10.1001/jama.2021.0202
- 4. Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a Neutralizing
- Antibody Cocktail, in Outpatients with Covid-19. N Engl J Med. Dec 17
- 340 2020;doi:10.1056/NEJMoa2035002
- 5. Webb BJ, Buckel W, Vento T, et al. Real-World Effectiveness and Tolerability of
- 342 Monoclonal Antibodies for Ambulatory Patients with Early COVID-19. 3/17/2021
- 343 2021;doi:<u>https://doi.org/10.1101/2021.03.15.21253646</u>
- 344 6. Ault A. Rollout of COVID Monoclonal Antibodies Lacked Unified Plan: Expert Panel.
- Accessed 23 Mar 2021. Available at: <u>https://www.medscape.com/viewarticle/945223</u>.
- 346 7. Bariola JR, McCreary EK, Khadem T, Snyder GM, Wadas RJ, Nace DA, White DB,
- 347 Yealy DM, Schmidhofer M. Establishing a Distribution Network for COVID-19 Monoclonal

Antibody Therapy Across a Large Health System During a Global Pandemic. Open Forum InfectDis. 2021. In press.

8. Reitz KM, Marroquin OC, Zenati MS, et al. Association Between Preoperative

351 Metformin Exposure and Postoperative Outcomes in Adults With Type 2 Diabetes. *JAMA Surg*.

352 Jun 1 2020;155(6):e200416. doi:10.1001/jamasurg.2020.0416

9. FDA News Release. Coronavirus (COVID-19) update: FDA authorizes monoclonal

antibody for treatment of COVID-19. Published November 9, 2020. Accessed November 13,

355 2020. <u>https://bit.ly/2HesBBs</u>.

10. Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of

357 Confounding in Observational Studies. *Multivariate Behav Res.* May 2011;46(3):399-424.

358 doi:10.1080/00273171.2011.568786

11. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational

studies for causal effects. Biometrika. 1983; 70: 41-55. <u>https://doi.org/10.1093/biomet/70.1.41</u>.

12. Lim ZJ, Subramaniam A, Ponnapa Reddy M, et al. Case Fatality Rates for Patients with

362 COVID-19 Requiring Invasive Mechanical Ventilation. A Meta-analysis. Am J Respir Crit Care

363 *Med.* Jan 1 2021;203(1):54-66. doi:10.1164/rccm.202006-2405OC

13. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities,

and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area.

366 *JAMA*. May 26 2020;323(20):2052-2059. doi:10.1001/jama.2020.6775

14. Bajaj V, Gadi N, Spihlman AP, Wu SC, Choi CH, Moulton VR. Aging, Immunity, and

368 COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections? Front

369 *Physiol*. 2020;11:571416. doi:10.3389/fphys.2020.571416

- 15. Tartof SY, Qian L, Hong V, et al. Obesity and Mortality Among Patients Diagnosed With
- 371 COVID-19: Results From an Integrated Health Care Organization. Ann Intern Med. Nov 17
- 372 2020;173(10):773-781. doi:10.7326/m20-3742
- 16. Benchimol EI, Smeeth L, Guttmann A, et al. The REporting of studies Conducted using
- 374 Observational Routinely-collected health Data (RECORD) statement. *PLoS Med.* Oct
- 375 2015;12(10):e1001885. doi:10.1371/journal.pmed.1001885
- 17. Chen P, Nirula A, Heller B, et al. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in
- 377 Outpatients with Covid-19. *N Engl J Med.* Jan 21 2021;384(3):229-237.
- doi:10.1056/NEJMoa2029849
- 18. Liu H, Wei P, Zhang Q, et al. 501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose
- binding to Bamlanivimab in vitro. *bioRxiv*. Feb 16 2021;doi:10.1101/2021.02.16.431305
- 19. US Department of Health and Human Services. Update on COVID-19 variants and
- impact on bamlanivimab distribution. Available from:
- 383 https://www.phe.gov/emergency/events/COVID19/investigation-
- 384 <u>MCM/Bamlanivimab/Pages/default.aspx</u>. Accessed March 24th, 2021.
- 385

386 TABLES

387 Table 1. Comparison of Characteristics of Unmatched and Propensity Matched Patients

| | | | Unmatched | Propensity Matched | | | |
|--|-------------|------------|-------------|---------------------------|------------|-------------|---------|
| | Age Group | Infused | Not infused | | Infused | Not infused | |
| Characteristic | Matching* | (N=463) | (N=16565) | p-value | (N=234) | (N=234) | p-value |
| Age, mean, SD | A,B,C | 66.3, 14.4 | 55.3, 19.2 | <.0001 | 67.2, 13.0 | 66.1, 15.0 | 0.4079 |
| Female gender, % | A,B,C | 53.3 | 59.6 | 0.0065 | 53.4 | 50.9 | 0.5788 |
| Black race, % | B,C | 5.7 | 9.3 | 0.0099 | 5.1 | 8.5 | 0.1429 |
| Charlson Comorbidity Index Score, mean, SD | A,B,C | 1.7, 1.8 | 0.9, 1.3 | <.0001 | 1.6, 1.7 | 1.5, 1.7 | 0.5540 |
| Allegheny as county of residence, % | A,B,C | 49.7 | 34.8 | <.0001 | 51.3 | 46.6 | 0.3091 |
| History of cirrhosis, % | В | 3.0 | 0.9 | <.0001 | 3.0 | 1.3 | 0.2010 |
| History of adrenal insufficiency, % | А | 7.6 | 3.6 | 0.0012 | 7.7 | 5.1 | 0.2575 |
| History of end stage renal disease, % | A,B,C | 3.0 | 0.9 | 0.0008 | 3.0 | 3.8 | 0.6109 |
| History of morbid obesity, % | A,B,C | 27.4 | 24.9 | 0.3701 | 26.9 | 22.2 | 0.2376 |
| History of hypertension, % | С | 68.2 | 49.8 | <.0001 | 73.5 | 75.2 | 0.6720 |
| DOACS, % | В | 11.8 | 5.6 | <.0001 | 11.1 | 14.1 | 0.3296 |
| Hydroxychloroquine, % | В | 3.8 | 1.5 | 0.0051 | 3.8 | 3.0 | 0.6109 |
| Immunomodulators, % | В | 3.8 | 1.5 | 0.0043 | 3.4 | 2.1 | 0.3988 |
| Statins, % | В | 59.1 | 36.9 | <.0001 | 58.5 | 61.1 | 0.5716 |
| Current tobacco use, % | Not matched | 7.2 | 9.0 | 0.3302 | 6.8 | 4.3 | 0.2303 |
| Alcohol use, % | Not matched | 53.8 | 51.7 | 0.5193 | 54.1 | 46.5 | 0.1025 |
| Illicit drug use, % | Not matched | 1.5 | 2.8 | 0.0952 | 2.6 | 2.6 | 1.0000 |
| History of diabetes, % | Not matched | 30.3 | 22.1 | <.0001 | 32.9 | 31.6 | 0.7667 |
| History of hyperlipidemia, % | Not matched | 75.5 | 51.2 | <.0001 | 75.6 | 71.4 | 0.2949 |
| History of atrial fibrillation, % | Not matched | 15.0 | 6.0 | <.0001 | 14.5 | 12.8 | 0.5905 |
| History of coronary artery disease, % | Not matched | 19.5 | 11.8 | <.0001 | 19.7 | 26.1 | 0.0987 |
| History of congestive heart failure, % | Not matched | 13.5 | 6.5 | <.0001 | 14.5 | 15.8 | 0.6991 |
| History of COPD, % | Not matched | 24.9 | 17.4 | <.0001 | 25.6 | 22.2 | 0.3861 |
| History of obstructive sleep apnea, % | Not matched | 30.5 | 18.7 | <.0001 | 30.3 | 29.9 | 0.9197 |

| History of pulmonary hypertension, % | Not matched | 4.9 | 1.7 | <.0001 | 6.4 | 5.1 | 0.5520 |
|--------------------------------------|-------------|------|------|--------|------|------|--------|
| ACE Inhibitors, % | Not matched | 21.9 | 18.0 | 0.1133 | 21.4 | 20.1 | 0.7323 |
| Antidepressants, % | Not matched | 32.5 | 32.6 | 0.9794 | 32.5 | 35.0 | 0.5575 |
| Beta blockers, % | Not matched | 38.0 | 23.9 | <.0001 | 37.2 | 41.9 | 0.2983 |
| Corticosteroids, % | Not matched | 38.4 | 45.4 | 0.0052 | 36.8 | 40.2 | 0.4472 |


388 *A: Age < 55 years; B: Age 55 to < 65 years; C: Age 65 years and older.


| Outcome | | er of Events | 28-Day Ev | vent Rate (%) | | ds Ratio Estimat | Odds Ratio Estimates | | |
|---|--------------------|------------------------|-----------|---------------|---------------|------------------|-----------------------------|--|--|
| All Patients | Infused (n=234) | Not Infused (n=234) | Infused | Not Infused | Odds Ratio | 95% CI | p-value | | |
| Hospitalization or mortality | 16 | 45 | 6.8 | 19.2 | 0.31 | 0.17, 0.56 | 0.00001 | | |
| Hospitalization or ED visit without hospitalization | 28 | 50 | 12.0 | 21.4 | 0.50 | 0.43, 0.83 | 0.007 | | |
| ED visit without hospitalization | 16 | 15 | 6.4 | 6.4 | 1.07 | 0.52, 2.22 | 0.85 | | |
| Hospitalization | 15 | 38 | 6.4 | 16.2 | 0.35 | 0.19, 0.66 | 0.001 | | |
| Mortality | 4 | 12 | 1.7 | 5.1 | 0.32 | 0.10, 1.01 | 0.05 | | |
| Age < 55 years | (n=42) | (n=42) | | | | | | | |
| Hospitalization or mortality | 2 | 3 | 4.8 | 7.1 | 0.65 | 0.10, 4.10 | 0.65 | | |
| Hospitalization or ED visit without hospitalization | 7 | 5 | 16.7 | 11.9 | 1.48 | 0.43, 5.10 | 0.53 | | |
| ED visit without hospitalization | 6 | 4 | 14.3 | 9.5 | 1.58 | 0.41, 6.08 | 0.50 | | |
| Hospitalization | 2 | 3 | 4.8 | 7.1 | 0.65 | 0.10, 4.10 | 0.65 | | |
| Mortality | 0 | 0 | 0.0 | 0.0 | | | | | |
| Age 55 to < 65 years | (n=34) | (n=34) | | | | | | | |
| Hospitalization or mortality | 2 | 6 | 5.9 | 17.6 | 0.29 | 0.05, 1.56 | 0.15 | | |
| Hospitalization or ED visit without hospitalization | 2 | 7 | 5.9 | 20.6 | 0.24 | 0.05, 1.26 | 0.09 | | |
| ED visit without hospitalization | 1 | 2 | 2.9 | 5.9 | 0.49 | 0.04, 5.61 | 0.56 | | |
| Hospitalization | 2 | 5 | 5.9 | 14.7 | 0.36 | 0.06, 2.01 | 0.25 | | |
| Mortality | 0 | 1 | 0.0 | 2.9 | 0.0 | | | | |
| Age 65 years and older | (n=158) | (n=158) | | | | | | | |
| Hospitalization or mortality | 12 | 36 | 7.6 | 22.8 | 0.28 | 0.14, 0.56 | 0.0003 | | |
| Hospitalization or ED visit without hospitalization | 19 | 38 | 12.0 | 24.0 | 0.43 | 0.24, 0.79 | 0.006 | | |
| ED visit without hospitalization | 9 | 9 | 5.7 | 5.7 | 1.00 | 0.39, 2.59 | 1.0 | | |
| Hospitalization | 11 | 30 | 7.0 | 19.0 | 0.32 | 0.15, 0.66 | 0.002 | | |
| Mortality | 4 | 11 | 2.5 | 7.0 | 0.35 | 0.11, 1.11 | 0.08 | | |


Table 2. Propensity Matched Event Rates and Odds Ratios of Study Outcomes Overall and Stratified by Age Group

391 FIGURE LEGENDS

| 393 | Figure 1a. Frequency of 28-day hospitalization or mortality (primary outcome), and |
|-----|---|
| 394 | hospitalization or Emergency Department visit without hospitalization (secondary outcome) |
| 395 | among the matched patients receiving monoclonal antibody (orange bars) versus those not |
| 396 | receiving monoclonal antibody infusion (blue bars). P-values are from the logistic regression |
| 397 | models. |
| 398 | |
| 399 | Figure 1b. Frequency of the individual elements of the composite primary and secondary |
| 400 | outcomes including Emergency Department visit without hospitalization, hospitalization, and |
| 401 | mortality among the matched patients receiving monoclonal antibody (orange bars) versus those |
| 402 | not receiving monoclonal antibody infusion (blue bars). P-values are from the logistic regression |
| 403 | models. |
| 404 | |
| 405 | Figure 2. Among all study patients receiving monoclonal antibody infusion, comparison of |
| 406 | crude 28-day outcome rates by timing of infusion. Blue bars (0 to 2 days), orange bars (3 to 4 |
| 407 | days), grey bars (5 to 7 days), yellow bars (8 days or more). |
| 408 | |







414 SUPPLEMENTAL MATERIALS

Supplemental Table 1. Variables selected for propensity score adjustment

| | X 7 ' 11 | | | | | | | | |
|----------------------|--|--|--|--|--|--|--|--|--|
| Analysis Group | Variables | | | | | | | | |
| Age < 55 years | Age | | | | | | | | |
| | Gender | | | | | | | | |
| | Residence in Allegheny county | | | | | | | | |
| | Morbid obesity | | | | | | | | |
| | History of renal insufficiency | | | | | | | | |
| | History of end stage renal disease | | | | | | | | |
| | History of irritable bowel syndrome | | | | | | | | |
| | Charlson Comorbidity Index score | | | | | | | | |
| | Model c-statistic: 0.826 | | | | | | | | |
| Age 55 to < 65 years | Age | | | | | | | | |
| | Gender | | | | | | | | |
| | Race | | | | | | | | |
| | Residence in Allegheny county | | | | | | | | |
| | Morbid obesity | | | | | | | | |
| | History of cirrhosis | | | | | | | | |
| | History of end stage renal disease | | | | | | | | |
| | Charlson Comorbidity Index score | | | | | | | | |
| | Medications: direct oral anticoagulants, hydroxychloroquine, | | | | | | | | |
| | immunomodulators, statins | | | | | | | | |
| | Model c-statistic: 0.852 | | | | | | | | |
| Age \geq 65 years | Age | | | | | | | | |
| | Gender | | | | | | | | |
| | Race | | | | | | | | |
| | Residence in Allegheny county | | | | | | | | |
| | Morbid obesity | | | | | | | | |
| | History of hypertension | | | | | | | | |
| | Charlson Comorbidity Index score | | | | | | | | |
| | Model c-statistic: 0.670 | | | | | | | | |

418 **Supplemental Table 2.** Comparison of days to individual outcomes between patients receiving

419 monoclonal antibody infusion and patients not receiving monoclonal antibody infusion, in both

| | | | Infused | l | | Not Infused | | |
|------------|----------------------------------|----|---------|---------|------|-------------|-------|---------|
| | Outcome | Ν | Median | IQR | Ν | Median | IQR | p-value |
| At-risk | ED visit without hospitalization | 30 | 7 | 4, 15 | 1040 | 4 | 2, 10 | 0.04 |
| population | Hospitalization | 31 | 8 | 2, 15 | 1379 | 5 | 2, 11 | 0.40 |
| | Mortality | 7 | 13 | 5,23 | 301 | 11 | 7,16 | 0.38 |
| Matched | ED visit without hospitalization | 16 | 7 | 2.5, 14 | 15 | 4 | 2, 8 | 0.20 |
| study | Hospitalization | 15 | 5 | 1, 21 | 38 | 8.5 | 3, 16 | 0.66 |
| population | Mortality | 4 | 18 | 8.5, 24 | 12 | 9.5 | 9, 11 | 0.16 |

420 the at-risk population and matched study population.

421 Note: ED, Emergency Department; IQR, interquartile range

Supplemental Table 3. RECORD statement

| | Item No. | STROBE items | Location in manuscript where items are reported | RECORD items | Location in manuscript where items are reported |
|----------------------|-------------|---|--|---|--|
| Title and abstrac | | | T | | T ·· |
| | 1 | (a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found | Page 3; Lines 41-46 | RECORD 1.1: The type of data used should be specified in the title or abstract. When possible, the name of the databases used should be included. RECORD 1.2: If applicable, the geographic region and timeframe within which the study took place should be reported in the title or abstract. RECORD 1.3: If linkage between databases was conducted for the study, this should be clearly stated in the title or abstract. | Page 3; Lines 41- 46 |
| Introduction | | | | | |
| Background rationale | 2 | Explain the scientific background and rationale for the investigation being reported | Page 4; Lines 65-67, 73-77 | | |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses | Page 4; Lines 70-72 (hypothesis), Lines 73-77 (objectives) | | |
| Methods | | | | | |
| Study Design | 4 | Present key elements of study design early in the paper | Page 6; Lines 110-121 | | |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | Page 5; Lines 81-84 (Setting/locations) Page 6; Lines 104-105 (relevant dates of exposure), ,Lines 110- 112 | | |

| | | | Page 10; 196-199 (follow up) | | |
|------------------------------|---|---|---|---|--|
| Participants | 6 | (a) Cohort study - Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up Case-control study - Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls Cross-sectional study - Give the eligibility criteria, and the sources and methods of selection of participants (b) Cohort study - For matched studies, give matching criteria and number of exposed and unexposed Case-control study - For matched studies, give matching criteria and the number of controls per case | Page 6; Lines 104-110 (eligibility), Lines 113-121 (comparator group and period of follow up) Page 8; Lines 151-161 (PS matching process) | RECORD 6.1: The methods of study population selection (such as codes or algorithms used to identify subjects) should be listed in detail. If this is not possible, an explanation should be provided. RECORD 6.2: Any validation studies of the codes or algorithms used to select the population should be referenced. If validation was conducted for this study and not published elsewhere, detailed methods and results should be provided. RECORD 6.3: If the study involved linkage of databases, consider use of a flow diagram or other graphical display to demonstrate the data linkage process, including the number of individuals with linked data at each stage. | Page 5; Lines 96- 102 (database) |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable. | Page 6-7; Lines 123- 131 (outcomes) Page 7-8; Lines 142- 150, 151-161 (addressing confounders) | RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided. If these cannot be reported, an explanation should be provided. | Page 6-7; Lines 123-131 (Codes for primary outcomes) Supplemental Table 1 (PS variables for confounding) |
| Data sources/ measurement | 8 | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | Page 5; Lines 91-102 (sources of data) Page 7-9; Lines 133- 134, 140-192 (method of assessment and data analysis) | | |

| Bias | 9 | Describe any efforts to address potential sources of bias | Page 7-9; Lines 132- 192 | | |
|-------------------------------------|----|--|-----------------------------|---|--------------------------|
| Study size | 10 | Explain how the study size was arrived at | Page 10; Lines 196- 209 | | |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen, and why | Page 8; Lines 162-163 | | |
| Statistical methods | 12 | (a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) <i>Cohort study</i> - If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> - If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> - If applicable, methods taking account of sampling strategy (e) Describe any sensitivity analyses | Page 7-9; Lines 132- 192 | | |
| Data access and cleaning methods | | | | RECORD 12.1: Authors should describe the extent to which the investigators had access to the database population used to create the study population. RECORD 12.2: Authors should provide information on the data cleaning methods used in the study. | Page 5; Lines 91- 102 |
| Linkage | | | | RECORD 12.3: State whether the study included person-level, institutional-level, or other data linkage across two or more databases. The methods of linkage and | Page 5; Lines 91- 102 |

| | | | | methods of linkage quality evaluation should be provided. | |
|------------------|----|--|---|--|---------------------------|
| Results | | | · | · · | |
| Participants | 13 | (a) Report the numbers of individuals at each stage of the study (<i>e.g.</i>, numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed) (b) Give reasons for non- participation at each stage. (c) Consider use of a flow diagram | Page 10; Lines 196- 209 | RECORD 13.1: Describe in detail the selection of the persons included in the study (<i>i.e.</i> , study population selection) including filtering based on data quality, data availability and linkage. The selection of included persons can be described in the text and/or by means of the study flow diagram. | Page 10; Lines 196-209 |
| Descriptive data | 14 | (a) Give characteristics of study participants (<i>e.g.</i>, demographic, clinical, social) and information on exposures and potential confounders (b) Indicate the number of participants with missing data for each variable of interest (c) <i>Cohort study</i> - summarise follow-up time (<i>e.g.</i>, average and total amount) | (a) Page 10, Lines 202- 209 Pages 20-21, Lines 287-288, Table 2 (b) Page 8, Lines 158-161 Page 12, Lines 246- 247 (c) Page 6, Lines 110-112 and 116-121. Time to event data not analyzed by study design. | | |
| Outcome data | 15 | <i>Cohort study</i> - Report numbers of outcome events or summary measures over time <i>Case-control study</i> - Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> - Report numbers of outcome events or summary measures | Page 10, Lines 213- 214 Page 22, Lines 389- 390, Table 2 Page 24, Lines 409- 412 Page 27, Lines 418- 412, Supplemental Table 2 Page 34, Lines 424- 427, Supplemental Table 4 | | |

| Main results | 16 | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | (a) Page 10, Lines 202-209 (unadjusted) Pages 10-11, Lines 210-224 (adjusted) Page 22, Lines 389-390, Table 2 (both) (b) N/A, all variables are continuous or binary. Subgroup age categories are defined. (Page 7, Lines 140-142) (c) N/A | | |
|----------------|----|---|--|---|--|
| Other analyses | 17 | Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses | Pages 11-12, Lines 225-247 | | |
| Discussion | | | | | |
| Key results | 18 | Summarise key results with reference to study objectives | Page 12, Lines 250- 258 Pages 14-15, Lines 305-309 | | |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | Page 13, Lines 278- 290 | RECORD 19.1: Discuss the implications of using data that were not created or collected to answer the specific research question(s). Include discussion of misclassification bias, unmeasured confounding, missing data, and changing eligibility over time, as they pertain to the study being reported. | Page 8, Lines 151- 161 Pages 13-14, Lines 278-290 |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | Pages 14-15, Lines 305-310 | | |

| Generalisability | 21 | Discuss the generalisability (external validity) of the study results | Page 14, Lines 291- 298 | | |
|--|----|---|--|--|---------------------------|
| Other Information | L | | | | |
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | Page 16, Line 322 (no external funding source) | | |
| Accessibility of protocol, raw data, and programming code | | | | RECORD 22.1: Authors should provide information on how to access any supplemental information such as the study protocol, raw data, or programming code. | Not available/provided |

423 *Checklist is protected under Creative Commons Attribution (<u>CC BY</u>) license.


424 Supplemental Table 4. Composite primary and secondary outcomes, and outcomes comprising the composite outcomes, in an


- 425 unmatched cohort of patients receiving monoclonal antibody infusion and an at-risk population of patients not receiving monoclonal
- 426 antibody infusion

| | All Patients | | | | Pa | tients with P | ropensity S | core | | | |
|--|--------------------|------------------------------|--------------|-------------------|--------------------|------------------------------|----------------|----------------|----------------------|------------|---------|
| | Number of Events | | Event | vent Rate (%) Nur | | r of Events | Event Rate (%) | | Odds Ratio Estimates | | |
| | Infused (n=463) | Not Infused (n=16,565) | Infused | Not Infused | Infused (n=236) | Not Infused (n=16,515) | Infused | Not Infused | Adj. OR | 95%CI | P-value |
| Hospitalization or mortality | 33 | 1516 | 7.1 | 9.1 | 17 | 1507 | 7.2 | 9.1 | 0.41 | 0.24, 0.70 | 0.001 |
| Hospitalization or ED visit without hospitalization | 56 | 2254 | 12.1 | 13.6 | 29 | 2244 | 12.3 | 13.6 | 0.60 | 0.40, 0.91 | 0.02 |
| ED visit without hospitalization | 30 | 1040 | 6.5 | 6.3 | 16 | 1037 | 6.8 | 6.3 | 1.05 | 0.63, 1.77 | 0.85 |
| Hospitalization | 31 | 1379 | 6.7 | 8.3 | 16 | 1371 | 6.8 | 8.3 | 0.44 | 0.25, 0.77 | 0.004 |
| Mortality | 7 | 301 | 1.5 | 1.8 | 5 | 300 | 2.1 | 1.8 | 0.37 | 0.12, 1.16 | 0.29 |

427 Note: ED, Emergency Department; OR, odds ratio; 95%CI, 95% confidence interval

Supplemental Figure 1. Frequency of composite hospitalization or mortality outcome among





431 Note: BMI, body mass index in units of kilograms per meter squared.